Quanta Therapeutics

Executive Summary

Quanta Therapeutics is a private, oncology-focused biotech company based in South San Francisco, developing small molecule drugs that target historically challenging protein-protein interactions (PPIs) in cancer signaling pathways, with a primary focus on RAS and related oncogenic drivers. Founded in 2018 and currently in Phase 1 stage, the company has raised approximately $50 million to advance its discovery engine and lead programs. Quanta's approach aims to drug intracellular targets that were previously considered undruggable, potentially addressing significant unmet needs in oncology. The company's lead programs target RAS mutations, which are prevalent in many cancers including pancreatic, lung, and colorectal cancers. While still in early clinical development, Quanta's innovative platform and experienced management team position it to make meaningful progress in a competitive but high-impact area of cancer therapeutics. The upcoming catalysts, including Phase 1 data readouts and potential financing, will be critical for validating its technology and advancing its pipeline.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 data readout for lead RAS program35% success
• Q4 2026Initiation of a new preclinical program targeting a novel PPI50% success
• Q3 2026Series B financing or partnering deal60% success